Oric Pharmaceuticals, Inc. (ORIC) Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

1.27 M

Shareholding (Mar 2025)

FII

11.50%

Held by 70 FIIs

DII

26.85%

Held by 34 DIIs

Promoter

37.01%

How big is Oric Pharmaceuticals, Inc.?

22-Jun-2025

As of Jun 18, Oric Pharmaceuticals, Inc. has a market capitalization of 769.57 million and reported net sales of 0.00 million with a net profit of -132.86 million over the latest four quarters. The balance sheet as of Dec'24 shows shareholder's funds of 243.12 million and total assets of 276.73 million.

What does Oric Pharmaceuticals, Inc. do?

22-Jun-2025

Oric Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on overcoming cancer resistance, with a market cap of approximately $769.57 million and a recent net profit of -$30 million. The company does not currently pay dividends and has a negative return on equity of -60.46%.

Who are in the management team of Oric Pharmaceuticals, Inc.?

22-Jun-2025

As of March 2022, the management team of Oric Pharmaceuticals, Inc. includes Dr. Richard Heyman (Independent Chairman), Dr. Jacob Chacko (CEO and Director), Dr. Lori Kunkel (Director), and Mr. Peter Svennilson (Board member).

Is Oric Pharmaceuticals, Inc. technically bullish or bearish?

28-Oct-2025

As of October 24, 2025, Oric Pharmaceuticals, Inc. shows a bullish technical trend supported by positive MACD and moving averages, despite some mild bearish signals from KST and OBV, and has significantly outperformed the S&P 500 year-to-date.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 1,020 Million ()

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.86

Return on Equity

-42.36%

Price to Book

3.15

Revenue and Profits:

Net Sales:

(Quarterly Results - Jun 2025)

Net Profit:

-36 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

7.45%

6 Months

35.6%

1 Year

18.65%

2 Years

37.73%

3 Years

171.19%

4 Years

-19.28%

5 Years

-68.06%

Oric Pharmaceuticals, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

Is Oric Pharmaceuticals, Inc. technically bullish or bearish?

As of 24 October 2025, the technical trend for Oric Pharmaceuticals, Inc. has changed from mildly bullish to bullish. The MACD is bullish on both the weekly and monthly time frames, and Bollinger Bands also indicate a bullish stance for both periods. Daily moving averages are bullish, supporting the overall positive trend. However, the KST is mildly bearish on both weekly and monthly charts, and the OBV shows a mildly bearish trend on the weekly but no trend on the monthly. Dow Theory indicates a mildly bullish stance on both time frames. In terms of performance, Oric Pharmaceuticals has outperformed the S&P 500 across multiple periods, with a year-to-date return of 62.33% compared to the S&P 500's 15.47%, and a one-year return of 55.21% versus 16.90%. Overall, the current technical stance is bullish with moderate strength, driven primarily by the positive MACD and moving averages....

Is Oric Pharmaceuticals, Inc. technically bullish or bearish?

As of 24 October 2025, the technical trend for Oric Pharmaceuticals, Inc. has changed from mildly bullish to bullish. The MACD is bullish on both weekly and monthly time frames, and Bollinger Bands also indicate a bullish stance in both periods. Daily moving averages confirm a bullish trend as well. However, the KST shows a mildly bearish signal on both weekly and monthly charts, and the OBV is mildly bearish on the weekly but shows no trend monthly. Dow Theory indicates a mildly bullish position on both time frames. In terms of performance, Oric Pharmaceuticals has significantly outperformed the S&P 500 across multiple periods, with a year-to-date return of 62.33% compared to the S&P 500's 15.47%, and a one-year return of 55.21% versus 16.90%. Overall, the current technical stance is bullish with strong indicators supporting this view....

Is Oric Pharmaceuticals, Inc. technically bullish or bearish?

As of 24 October 2025, the technical trend for Oric Pharmaceuticals, Inc. has changed from mildly bullish to bullish. The weekly and monthly MACD indicators are bullish, and Bollinger Bands also reflect a bullish stance across both time frames. Daily moving averages are bullish as well. However, the KST is mildly bearish on both weekly and monthly charts, and the OBV shows a mildly bearish trend weekly with no trend monthly. Dow Theory indicates a mildly bullish position on both weekly and monthly bases. In terms of performance, Oric Pharmaceuticals has significantly outperformed the S&P 500 across multiple periods, with a year-to-date return of 62.33% compared to the S&P 500's 15.47%, and a one-year return of 55.21% against 16.90%. Overall, the current technical stance is bullish, driven primarily by strong MACD and Bollinger Band signals....

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

-219.48%

EBIT to Interest (avg)

-98.44

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.91

Sales to Capital Employed (avg)

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

3.02

EV to EBIT

-3.15

EV to EBITDA

-3.18

EV to Capital Employed

24.03

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

-762.55%

ROE (Latest)

-60.46%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Bullish

RSI

No Signal

Bollinger Bands

Mildly Bullish

Moving Averages

Mildly Bullish (Daily)

KST

Mildly Bearish

Dow Theory

No Trend

Mildly Bullish

OBV

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Mar 2025

Shareholding Compare (%holding)

Majority shareholders

Strategic Entities

Domestic Funds

Held in 45 Schemes (24.64%)

Foreign Institutions

Held by 70 Foreign Institutions (11.5%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -13.75% vs -39.74% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-38.80",
          "val2": "-35.70",
          "chgp": "-8.68%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-36.40",
          "val2": "-32.00",
          "chgp": "-13.75%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -26.91% vs -13.02% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-141.80",
          "val2": "-109.70",
          "chgp": "-29.26%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-127.80",
          "val2": "-100.70",
          "chgp": "-26.91%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Jun'25

Jun'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-38.80

-35.70

-8.68%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-36.40

-32.00

-13.75%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -13.75% vs -39.74% in Jun 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-141.80

-109.70

-29.26%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-127.80

-100.70

-26.91%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -26.91% vs -13.02% in Dec 2023

All Annual Results

Company CV

About Oric Pharmaceuticals, Inc.

Oric Pharmaceuticals, Inc.

Pharmaceuticals & Biotechnology

ORIC Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on improving patients’ lives by overcoming resistance in cancer. The Company is focused on developing a diverse pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its experience within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. Its lead product candidate is ORIC-101. The Company’s ORIC-101 is a potent and selective small-molecule antagonist of the glucocorticoid receptor (GR), which has been linked to resistance to multiple classes of cancer therapeutics across a variety of solid tumors. The Company’s second product candidate, ORIC-533, is an orally bioavailable, small-molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy-and immunotherapy-based treatment regimens. Its third product candidate, ORIC-944, being developed for prostate cancer.

Company Coordinates

Company Details

240 E. Grand Ave., 2nd Floor , SOUTH SAN FRANCISCO CA : 94080

Tel: 1 650 3885600

http://oricpharma.com/

Registrar Details

Oric Pharmaceuticals, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

How big is Oric Pharmaceuticals, Inc.?

Watch in Real-Time

What does Oric Pharmaceuticals, Inc. do?

Who are in the management team of Oric Pharmaceuticals, Inc.?

Is Oric Pharmaceuticals, Inc. technically bullish or bearish?

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Is Oric Pharmaceuticals, Inc. technically bullish or bearish?

Is Oric Pharmaceuticals, Inc. technically bullish or bearish?

Is Oric Pharmaceuticals, Inc. technically bullish or bearish?

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Mar 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Annual Results Snapshot (Consolidated) - Dec'24

About Oric Pharmaceuticals, Inc.

Company Coordinates